Skip to main content
. 2022 Sep 25;14(9):e29573. doi: 10.7759/cureus.29573

Figure 1. Cutaneous metastases demonstrating treatment response.

Figure 1

(A-B) Cutaneous lesions prior to combined treatment with SBRT, TVEC, and ipilimumab. (C-D) Cutaneous lesions after treatment with SBRT and TVEC followed by ipilimumab.

SBRT, stereotactic body radiation therapy; TVEC, talimogene laherparepvec